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Abstract
Amitriptyline is a tricyclic antidepressant, considered the treatment of choice for different types of chronic pain, 
including chronic myofascial pain. Its antinociceptive property is independent of its antidepressant effect. Although 
its analgesic mechanism is not precisely known, it is believed that the serotonin reuptake inhibition in the central 
nervous system plays a fundamental role in pain control. Although this medication is widely used in the prevention 
of chronic tension-type headache, few studies have investigated the efficacy of this treatment and the published re-
sults are contradictory. The objective of this article was to review the literature published on the use of amitriptyline 
in the prophylactic treatment of chronic tension-type headache, considering the level of scientific evidence of the 
different studies using the SORT criteria. From this review, 5 articles of evidence level 1, and another 5 articles of 
evidence level 2 were selected. Following analysis of the 10 studies, and in function of their scientific quality, a level 
A recommendation was made in favor of using amitriptyline in the treatment of chronic tension-type headache.
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Introduction
Tension-type headache (TTH) is described as a dull, non 
pulsatile pain, affecting the entire head, of oppressive and 
progressive character, moderate or severe intensity, variable 
duration (up to several days) and lacking the typical fea-
tures of migraine. In 90% of cases the pain is bilateral, the 
typical location being in the occipital, parietal, temporal 
and frontal areas. Occasionally nauseas, photophobia or 
phonophobia can appear, with or without associated dys-
function of the pericranial muscles. Although the duration 
and intensity of the pain is variable, this headache is not 
as debilitating as migraine, and sufferers are usually able to 
continue their daily activities. It is considered that migraine 
and TTH constitute the same physiopathologic process, but 
with different clinical manifestations. Migraine possibly 
represents a painful condition with an important vascular 
component, while TTH represents a painful condition with 
a greater myofascial component. The episodic nature of 
TTH has an average duration of 12 hours, although this can 
vary from 30 minutes up to 72 hours. Chronic tension-type 
headache (CTTH) is present for at least 15 days a month 
during a 6-month period (1,2).
Although TTH is the most frequent type of primary heada-
che (two thirds of the population have suffered an episodic 
TTH and 3% suffer from CTTH), its physiopathology is still 
the cause of controversy within the scientific community. 
Publication Types: Review
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For many years it has been thought that TTH was directly 
related with muscular tension. However, more recently it has 
been postulated that although muscular tension is usually 
present in most cases, it is possible that the origin is more 
central, due to the hyperexcitability of the trigeminal caudal 
nucleus and of other structures of the central nervous sys-
tem (CNS) that register, modulate and interpret head pain. 
This abnormality can reduce the pain threshold and make 
the patient perceive pericranial musculature contraction as 
painful. Precipitating factors of TTH have been identified as 
those that interact with the limbic system, and myofascial, 
or vascular structures; the most frequent being emotional 
stress, anxiety, depression and myofascial pain (3,4). This 
pathology type may also be induced, intensified or made 
chronic by analgesic abuse (5,6).
Amitriptyline (AMT) is a tricyclic antidepressant pos-
sessing an analgesic effect, and is therefore prescribed for 
different types of chronic pain, its analgesic property being 
independent of its antidepressive effect (7-10). However, 
the analgesic mechanism is not precisely known. Probably, 
serotonin (5-HT) and noradrenaline reuptake inhibition 
of the CNS plays a fundamental role in the control of the 
pain. CTTH is one of the chronic disorders in which AMT 
seems to have a positive effect (5,8,11).
The objective of this article was to review the literature 
published on the use of AMT in the treatment of CTTH, 
taking into account the level of scientific evidence and 
following the principals of evidence-based dentistry.
Material and Method
A PubMed-MEDLINE search was carried out of articles 
published from 1966 to 2006. The MeSH (Medical Subject 
Heading) keywords and headings were used for "CTTH" 
(chronic tension-type headache) to obtain a primary bank 
of articles on this pathology. The identified literature was 
then limited to studies in humans and articles written in 
English. A similar search was made for AMT (amitrip-
tyline). Both search types were in turn merged by means 
of the boolean operator "AND", thus linking the articles 
for CTTH and AMT. Two authors analyzed the searched 
articles to verify their pertinence to the topic under study. 
The irrelevant articles were discarded. Next, two of the 
authors stratified the scientific articles separately according 
to their level of scientific evidence using the SORT criteria 
(Strength of Recommendation Taxonomy) (tables 1, 2 and 
3). Subsequently, the authors compared their results and, in 
the event of disagreement, the results were discussed. When 
it was not possible to achieve a consensus regarding the level 
of scientific evidence of a certain article, a third author was 




A Recommendation based on consistent and good-quality, patient-oriented evidence (1)
B Recommendation based on inconsistent or limited-quality, patient-oriented evidence (1)
C
Recommendation based on consensus, usual practice, opinion, disease-oriented evidence 





Level 1 - good-quality, 
patient-oriented 
evidence
- SR/meta-analysis of high-
quality studies
- High-quality diagnostic 
cohort study
- SR/meta-analysis of RCTs with 
consistent findings
- High quality individual RCT
- All or none studies*
- SR/meta-analysis of good-
quality cohort studies
- Prospective cohort study 
with good follow-up
Level 2 - limited-
quality, patient-oriented 
evidence
- SR/meta-analysis of low-
quality studies or studies 
with inconsistent findings
- Cohort study or low-
quality case control study
- SR/meta-analysis of low-quality 
clinical trials or of studies with 
inconsistent findings
- Low-quality clinical trial
- Cohort study 
- Case control study
- SR/meta-analysis of lower-
quality cohort studies or with 
inconsistent results
- Retrospective cohort study 




Level 3 - other evidence - Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-
oriented evidence, or case series to study diagnosis, treatment, prevention or screening
Table 1. Strength of Recommendation Taxonomy (SORT).
(1) Patient-oriented evidence considers the following objectives: reduction of mortality and morbidity, improvement of the 
symptoms, better quality of life, reduced costs.
(2) Disease-oriented evidence comprises intermediate, histopathologic, physiologic and other surrogate or potentially useful results for 
improving the patient's quality of life (blood sugar, blood pressure, etc.) that may or not reflect the patient's actual improvement.
Table 2. Levels of scientific evidence. Abbreviations: SR = systematic review; RCT = randomized clinical trial.
* All or none: the treatment causes a dramatic change in the outcomes (such as antibiotics for meningitis or surgery for appendicitis).
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with the level of scientific evidence of the analyzed articles, 
a recommendation level was declared in favor of, or against 
the use of AMT for the treatment of CTTH.
Results
The PubMed-MEDLINE search provided 1148 articles 
on AMT and 194 articles for CTTH. As mentioned 
previously, both search strategies were interleaved. This 
provided a bank of 20 articles. The articles obtained were 
then analyzed to determine if  they were pertinent to the 
topic under study. Articles with significant methodological 
errors such as an insufficient patient sample, inadequate 
sample selection criteria, imprecise definition of the study 
groups, inadequate description of the analyzed variables, 
or incomplete and/or inadequate presentation of the re-
sults obtained in the study were discarded. Articles were 
also discarded with scientific evidence level 3.
This detailed analysis provided a total of  10 relevant 
articles. These articles were critically analyzed, and clas-
sified according to their level of scientific evidence. This 
analysis revealed 5 articles with level of scientific evidence 
2 and another 5 articles with level of scientific evidence 
1 (table 4).
In accordance with the principals of evidence-based den-
tistry, the analysis of the results revealed a type A recom-
mendation in favor of the use of AMT in the treatment 
of CTTH. 
Discussion
It is currently considered that CTTH is related with an 
alteration in serotonin (5-HT) reuptake. In patients with 
CTTH a higher reuptake of this amine has been found, 
with a consequently lower concentration in plasma and 
platelets. Although the exact mechanism of tricyclic anti-
depressants is unknown, especially AMT, they are effective 
in the prophylactic treatment of CTTH, serotonin uptake 
inhibition is considered an important factor in its thera-
peutic action (12-14). This fact has motivated the study of 
different selective serotonin inhibitors, such as ritanserin, 
buspirone or citalopram, among others (8,12,13,15-17).
Nappi et al. (12) compared the efficacy of  AMT with 
ritanserin, a long-acting, selective antagonist of 5-HT2 
receptors, in patients with depression coexisting with CTH. 
From the study results they concluded that the two drugs 
were effective in reducing pain. They found no statistically 
significant differences between either treatment, except in 
the first month of treatment in the AMT group who con-
sumed less analgesics than the ritanserin group (p<0.005). 
Very similar results are found when comparing AMT with 
buspirone, an agent that selectively interacts with an area 
different to the serotonin receptors, specifically 5-HT1A 
(15). Rampello et al. (13) carried out a randomized study, 
finding that AMT was more effective than citalopram, a 
selective reuptake inhibitor of this amine having better 
tolerance than AMT in the prophylactic treatment of 
Consistent
- Most studies found similar or at least coherent conclusions (coherence 
means that the differences are explainable)
or
-The high-quality meta-analysis and SR support the recommendation
Inconsistent
- Considerable variation among study findings and lack of coherence
- If  high-quality SR or meta-analyses exist, they do not find consistent 
evidence in favor of the recommendation
Authors and year Journal Scientific Evidence
Bendtsen and Jensen (2000) (16) Cephalalgia Level 1
Mitsikostas et al. (1997) (15) Acta Neurol Scand Level 1
Bendtsen et al. (1996) (8) J Neurol Neurosurg Psychiatry Level 1
Pfaffenrath et al. (1994) (14) Cephalalgia Level 1
Nappi et al. (1990) (12) Headache Level 1
Bettucci et al. (2006) (28) J Headache Pain Level 2
de Tommaso et al. (2005) (18) Neurol Sci Level 2
Rampello et al. (2004) (13) Neuro-psychobiology Level 2
Holroyd et al. (2001) (25) JAMA Level 2
Göbel et al. (1994) (5) Pain Level 2
Table 3. Consistency across studies. Abbreviation: SR = systematic revision.
Table 4. Level 1 and 2 studies that analyze the use of amitriptyline in prophylactic treatment of chronic 
tension headache.
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CTTH. Nevertheless, they recorded more adverse effects 
in the group treated with AMT that in that treated with 
the other drug. These were especially prominent in the 
first week of  treatment, reducing gradually over the 
remainder of the follow-up period. Those patients that 
did not respond satisfactorily to the monotherapy (AMT 
or citalopram) achieved a significant reduction, both for 
intensity and frequency of attacks, when both drugs were 
administered together (13). Bendtsen et al. in various 
publications (8,16,17), conclude that AMT significantly 
reduces CTTH when compared to a placebo. However, no 
significant clinical improvement was obtained in patients 
with CTTH who were administered citalopram. These 
authors (16), as well as Göbel et al. (5), observed that 
AMT is also able to significantly reduce pain on palpation 
of the pericranial musculature.
From the results of various studies (8,12,13,15-17), it has 
been deduced that since tricyclic antidepressants were 
more effective in controlling chronic pain than the selective 
serotonin reuptake inhibitors, the effect of AMT cannot 
be explained solely by its serotoninergic action, but that 
possibly it is also related with its wide pharmacodynamic 
spectrum (adrenergic, cholinergic and histaminergic ac-
tion). On the other hand, the effectiveness of the merged 
treatment (AMT and citalopram) obtained by Rampello 
et al. (13) in their study, may be explained by the probable 
synergic action of the two substances, potentiating the 
serotoninergic transmission.
In agreement with the hypothesis of  Bendtsen and 
Jensen(16), pain on palpation of the pericranial muscu-
lature may initiate a self-perpetuating cycle, in which the 
prolonged nociceptive afferent stimuli originating from 
the affected myofascial tissue create a central sensitization 
at the level of the dorsal horn of the trigeminal nucleus. 
This will cause a supraspinal sensitization and a greater 
stimulation of  the nociceptive cortical areas, that will 
contribute to increasing the pericranial muscular activity 
and the afferent painful stimuli. Based on this theory, 
de Tommaso et al. (18), carried out a case control study, 
concluding that both central (AMT) and peripheral (oc-
clusal ferule) treatments were able to break this cycle and 
improve the symptomatology of  CTTH. On the other 
hand, they recorded a statistically higher reduction in 
pain on pericranial muscular palpation, in those patients 
treated with an occlusal ferule than in those treated with 
AMT. It would have been interesting if  this authors (18) 
had also combined both therapeutic approaches, as the 
results would probably have been better than those ob-
tained separately.
Some authors (19-21) have suggested that the duration of 
the final period of exteroceptive suppression (ES2) of the 
temporal muscle activity is reduced in patients with CTTH, 
and that ES2 is partially controlled by the serotoninergic 
neuronal mechanisms. The results of an investigation pu-
blished by Bendtsen et al. (17), in which they evaluated the 
effect of AMT and citalopram in CTTH, demonstrated 
that only AMT significantly reduced ES2. However, Göbel 
et al. (5), were unable to detect any correlation between 
the duration of ES2 and treatment of CTTH with AMT. 
In any case, many studies (17,22-24) have questioned the 
importance of ES2 in CTTH, since they have found no 
significant correlation between the duration of ES2 and 
the clinical characteristics of this type of headache. 
Although tricyclic antidepressants, especially AMT, are 
considered the first line in prophylactic treatment of 
CTTH; behavioral therapies, relaxation techniques, biofee-
dback and stress management are also used in the handling 
of this type of pathology. Holroyd et al. (25), carried out 
a study examining the possibility that behavioral therapy 
intensified the results obtained with AMT in CTTH. They 
evaluated the separate and combined effects of AMT and 
stress management techniques. The results revealed that 
both treatments, alone or combined, were effective in re-
ducing both the intensity and frequency of the headaches 
and analgesic consumption. However, the combination of 
the two therapies provided a significant reduction (>50%) 
in the frequency of the headaches in a greater proportion 
of patients (2/3) than in the groups who only received 
monotherapy (1/3). Although this finding suggests that 
combined therapy can improve on the results obtained 
with monotherapy, it is true that no statistically significant 
relation was observed in relation to the other variables 
analyzed. In the group in which only stress management 
techniques were applied, the reduction in symptoms were 
not evident until the evaluation at 6 months.
The efficacy of AMT in preventing CTTH does not be-
come evident until 2-3 weeks after commencing therapy. 
This fact creates a negative psychological impact on the 
patient during the first phases of treatment. Tizanidine is 
an α2 agonist that acts as a central muscle relaxant, but 
also having an antinociceptive effect. Several clinical trials 
advocate tizanidine as a promising additional drug for 
the prevention of chronic headaches. However, its use as 
a monotherapy is not justified (26,27). In a study by Bet-
tucci et al. (28), the combination of tizanidine with AMT 
provided a significant reduction in frequency, intensity 
and duration of the symptoms during the first month of 
treatment when compared to AMT alone. At the end of 
the treatment (90 days) no significant differences between 
the two therapies were found. Therefore, the combination 
of  both drugs provided an immediate improvement in 
quality of life in these patients measured using the HIT6 
scale (28). However, some deficiencies in the methodolo-
gical design of this investigation should be highlighted, 
such as the small sample size and the fact that the study 
was not blinded.
Amitriptylinoxide is an antidepressant with a similar se-
dative effect as AMT on the noradrenergic, serotoninergic 
and anticholinergic systems in the CNS. In a study by 
Pfaffenrath et al. (14), the efficacy and tolerance of this 
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drug was compared to that of AMT (taken as the referen-
ce) and a placebo. No statistically significant differences 
were observed among the three groups with regard to the 
decrease in intensity, the duration or frequency of the hea-
daches, nor to the adverse effects. However, some authors 
(5), have criticized the results of this study, considering 
the parameters used to evaluate the effects of this drug 
as having little discriminant power.
Selective serotonin reuptake inhibitors have shown a 
greater tolerance than AMT, although in general, the side 
effects (xerostomia, drowsiness, nauseas, weight gain or 
increase in appetite, sleep alterations, vertigo, dizziness, 
tachycardia or abdominal pain, etc.) are usually slight 
or decrease gradually over time (12-15,28). However, on 
comparing AMT with a placebo, no differences between 
the two have been seen for the majority of adverse effects 
associated with tricyclic antidepressants; except in xeros-
tomia or drowsiness which were higher in the AMT group 
(5,25). These data are possibly due to the fact that the do-
sage of AMT administered in the prophylactic treatment 
of CTTH is relatively low. The recommended posology 
oscillates between 10 and 100 mg in a single dose before 
going to bed. The treatment begins with a low dosage 
(between 10 and 25 mg/day) increasing gradually until a 
considerable decrease or the total disappearance of the 
symptoms presented by the patient is obtained (12-16,18). 
Its prescription is contraindicated during the immediate 
recovery period after acute miocardiac infarction. It 
should be used with extreme precaution in patients with 
cardiovascular anomalies, convulsive crisis, glaucoma, and 
hepatic, renal or prostatic dysfunction, its use is also not 
recommended during the pregnancy (5).
Conclusions
CTTH is difficult to treat since its etiology is still not com-
pletely clear. Therefore, although the results obtained have 
not always been statistically significant for all the evaluated 
clinical parameters, AMT (10-100mg/day) can be consi-
dered as having demonstrated efficacy in the prophylactic 
treatment of CTTH. Nevertheless, the combination of this 
treatment with other drugs or with behavioral therapies 
can provide a greater therapeutic efficacy. The dosage 
of AMT administered in the treatment of CTTH is low, 
therefore the majority of patients tolerate the medication 
well and the adverse effects are negligible.
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